Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Cross Country Healthcare Holds Annual Stockholders Meeting

Tipranks - Fri Dec 12, 2025

Claim 50% Off TipRanks Premium and Invest with Confidence

Cross Country Healthcare ( (CCRN) ) has shared an update.

On December 9, 2025, Cross Country Healthcare held its Annual Meeting of Stockholders where several key proposals were voted on. The stockholders approved the election of directors for a one-year term, ratified the appointment of Deloitte & Touche as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the compensation of named executive officers on an advisory basis.

The most recent analyst rating on (CCRN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.

Spark’s Take on CCRN Stock

According to Spark, TipRanks’ AI Analyst, CCRN is a Neutral.

Cross Country Healthcare’s overall stock score is primarily impacted by its financial performance challenges, including declining revenue and profitability issues. The bearish technical indicators further weigh on the score. Valuation concerns, highlighted by a negative P/E ratio, also contribute to the lower score. The termination of the merger adds uncertainty, although the company shows some financial resilience through planned share repurchases.

To see Spark’s full report on CCRN stock, click here.

More about Cross Country Healthcare

Average Trading Volume: 658,897

Technical Sentiment Signal: Sell

Current Market Cap: $260.4M

Find detailed analytics on CCRN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.